A bipartisan group of lawmakers reintroduced legislation that would give FDA the authority to deny approval to opioids that aren’t clinically superior to those already on the market, coming just one month after an FDA-commissioned report concluded that FDA needs more authority from Congress to ensure new opioids are safer than existing ones and to better regulate advertising for those products. Reps. David Trone (D-MD) and Dan Meuser (R-PA) on Friday (March 3) reintroduced the Ensuring the FDA Fully Examines...